ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "OncoGenex Pharmaceuticals, Inc." (OGXI) Report Updated: Oct 27, 2014 | Print This Page

Get more stock ratings by Louis Navellier

"OncoGenex Pharmaceuticals, Inc." (OGXI)

Rating: Sell Volatility: Aggressive
Total Grade: D Industry: Biotechnology
Competitors: MNOV, CMRX, MDXG, MACK

Stock Analysis

Rating: Monthly View

A
B
C
D
F
October November December January February March April May June July August September

Rating: Weekly View

This Week: D down upgrade
Last Week: F same downgrade
Two Weeks Ago: D up no change
service keys

"OncoGenex Pharmaceuticals, Inc."© quotemedia

Company Profile

OncoGenex Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. The company’s products include Custirsen, which is in phase III clinical trials for the treatment of metastatic castrate resistant prostate cancer; and OGX-427, a product candidate in phase II clinical trials, which is designed to inhibit heat shock protein 27. Its pre clinical stage products include OGX-225 that is focused on reducing the production of insulin growth factor binding protein-2 (IGFBP) and IGFBP-5; and CSP-9222, a lead compound from a family of caspase activators. OncoGenex Pharmaceuticals, Inc. is headquartered in Bothell, Washington.

Recent News: "OncoGenex Pharmaceuticals, Inc."